ILET Trio 1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (1mg), Metformin (500mg), and Voglibose (0.2mg), formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestine, resulting in reduced postprandial hyperglycemia. This combination targets multiple pathophysiological defects in type 2 diabetes, providing comprehensive glycemic management. ILET Trio 1 Tablet SR is designed for sustained release, ensuring prolonged therapeutic effect and improved patient compliance by reducing dosing frequency. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or dual therapy. Caution is advised in patients with renal or hepatic impairment, and monitoring for hypoglycemia is essential due to the sulfonylurea component. Common adverse effects may include gastrointestinal disturbances and hypoglycemia. This medication should be used under medical supervision with regular monitoring of blood glucose and HbA1c levels to optimize treatment outcomes.